MedPath

Smoking Cessation for Young Adult Pacific Islanders: Motivating Pacifika Against Cigarettes and Tobacco

Not Applicable
Completed
Conditions
Smoking, Cigarette
Tobacco Use
Tobacco Smoking
Smoking Cessation
Tobacco Use Cessation
Smoking
Registration Number
NCT03238456
Lead Sponsor
Claremont Graduate University
Brief Summary

The current study aimed to test a culturally tailored program designed to help Pacific Islanders (PIs) between the ages of 18 and 30 quit smoking cigarettes by using a randomized controlled trial design with one intervention group and one control group.

Detailed Description

This randomized control trial (RCT) consisted of a baseline assessment (Wave 0) and three follow-up assessments (Waves 1-3). Follow-up assessments were conducted at 2 months, 5 months, and 8 months after the baseline assessment. The objective of the study was to test a culturally-tailored online program designed to help PI young adults quit smoking cigarettes. The online program contained (1) personalized, automated text messages, (2) interactive, online educational modules, and (3) an online forum.

Hypotheses for this study include:

1. Participants in the intervention program tailored to PIs would have significantly higher rates of abstinence, lower rates of relapse, and lower smoking frequency and intensity at each follow-up time point than those in the standard intervention program.

2. Participants with impaired affective decision capacity (low scores on Iowa Gambling Task (IGT)) would benefit more from the tailored intervention program than participants with normal affective decision capacity (high IGT scores).

3. Effects from the tailored intervention program would be more pronounced among participants with particular dispositional phenotypes (depression, hostility, impulsivity) and baseline severity of tobacco addiction (nicotine dependence).

4. High-intensity users of the tailored intervention program would be more successful than low intensity users in reducing the frequency and intensity of cigarettes smoked.

5. The tailored intervention program would have greater success at engaging and retaining participants than the standard intervention program.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
278
Inclusion Criteria
  • Self-identified as Native Hawaiian or Pacific Islander
  • Between the ages 18 and 30
  • Lived in Southern California
  • Would be living in Southern California for the next year
  • Owned a cell phone with a text messaging plan
  • Had access to a computer with internet for at least 2 hours per week
  • Smoked daily or most days of the week (>3 days)
  • Smoked at least 100 cigarettes in lifetime
Exclusion Criteria

• Was currently using another smoking cessation method

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of cigarettes smoked in last 30 days8 months

How many cigarettes has the participant smoked in the last 30 days?

Cigarette smoked in past 24 hours8 months

Has the participant smoked a cigarette in the past 24 hours?

Expired carbon monoxide (CO)8 months

Biomarker validation (expired CO) of self-reported tobacco use

Cigarette smoked in past 7 days8 months

Has the participant smoked a cigarette in the past 7 days?

Secondary Outcome Measures
NameTimeMethod
Number of cigarettes smoked in last 30 days5 months

How many cigarettes has the participant smoked in the last 30 days?

Cigarette smoked in past 7 days5 months

Has the participant smoked a cigarette in the past 7 days?

Cigarette smoked in past 24 hours5 months

Has the participant smoked a cigarette in the past 24 hours?

Expired carbon monoxide (CO)5 months

Biomarker validation (expired CO) of self-reported tobacco use

Trial Locations

Locations (2)

Claremont Graduate University

🇺🇸

Claremont, California, United States

California State University Fullerton

🇺🇸

Fullerton, California, United States

Claremont Graduate University
🇺🇸Claremont, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.